Akouos Interest Expense 2011-2026 | AKUS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Akouos

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-1.72 M	-287 K	-11 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-11 K	-1.72 M	-673 K

Quarterly Interest Expense Akouos

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-157 K	-126 K	-206 K	-	-477 K	-510 K	-447 K	-	9 K	-2 K	-2 K	-	-3 K	-2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
9 K	-510 K	-175 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Apellis Pharmaceuticals APLS	-133 K	$ 20.15	-2.68 %	$ 2.54 B	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	-15.9 M	$ 163.7	-1.61 %	$ 8.14 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
AbCellera Biologics ABCL	-2.71 M	$ 3.72	-2.75 %	$ 1.11 B	Canada
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Certara CERT	6.34 M	$ 7.16	1.49 %	$ 1.15 B	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	399 K	$ 25.91	-3.56 %	$ 694 M	USA
Codexis CDXS	-10.4 M	$ 0.99	-3.28 %	$ 72.7 M	USA
Catalyst Pharmaceuticals CPRX	25.7 M	$ 24.0	0.5 %	$ 2.93 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	1.26 M	$ 3.19	-4.64 %	$ 1.14 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 28.78	-1.44 %	$ 1.67 B	USA
Champions Oncology CSBR	73 K	$ 6.0	-1.15 %	$ 82 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	371 K	$ 3.67	-3.42 %	$ 116 M	France
Alector ALEC	13.2 M	$ 2.11	-4.75 %	$ 217 M	USA
KalVista Pharmaceuticals KALV	4.81 M	$ 15.68	-2.4 %	$ 779 M	Britain
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	48 K	$ 4.17	0.24 %	$ 296 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	7 K	$ 14.27	2.44 %	$ 5.92 B	Irlanda